X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JSP191 (briquilimab) is a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases. It is being evaluated as a conditioning agent in the treatment of chronic spontaneous urticaria & chronic inducible urticaria.
Lead Product(s): Briquilimab
Therapeutic Area: Immunology Product Name: JSP191
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
JSP191 (briquilimab) is a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases. It is being evaluated as a conditioning agent in the treatment of Fanconi Anemia.
Lead Product(s): Briquilimab
Therapeutic Area: Genetic Disease Product Name: JSP191
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2024
Details:
Jasper intends to use the net proceeds from the offering for continued advancement of its preclinical and clinical development programs of JSP191 (briquilimab) in mast-cell driven diseases such as CSU and Chronic Inducible Urticaria (CIndU).
Lead Product(s): Briquilimab
Therapeutic Area: Immunology Product Name: JSP191
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: RBC Capital Markets
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 06, 2024
Details:
JSP191 (briquilimab) is an investigational CD117 Inhibitor antibody drug given via subcutaneous injection, for the treatment of Chronic Spontaneous Urticaria.
Lead Product(s): Briquilimab
Therapeutic Area: Immunology Product Name: JSP191
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
JSP191 (Briquilimab) is a targeted, monoclonal antibody that inhibits c-KIT receptor, also known as CD117. It is being evaluated as a conditioning agent for cell and gene therapies such as for chronic spontaneous urticaria.
Lead Product(s): Briquilimab
Therapeutic Area: Immunology Product Name: JSP191
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
JSP191 (Briquilimab) is a targeted, monoclonal antibody that inhibits c-KIT receptor, also known as CD117. It is being evaluated as a conditioning agent for cell and gene therapies such as for myelodysplastic syndrome.
Lead Product(s): Briquilimab
Therapeutic Area: Oncology Product Name: JSP191
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
JSP191 (Briquilimab) is a targeted, monoclonal antibody that inhibits c-KIT receptor, also known as CD117. It is being evaluated as a conditioning agent for cell and gene therapies such as for fanconi anemia.
Lead Product(s): Briquilimab
Therapeutic Area: Genetic Disease Product Name: JSP191
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
JSP191 (briquilimab) is a targeted, monoclonal antibody that inhibits the cell-surface receptor c-KIT, also known as CD117. It is currently being evaluated as a primary therapeutic for mast cell diseases.
Lead Product(s): Briquilimab
Therapeutic Area: Genetic Disease Product Name: JSP191
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
JSP191 (briquilimab) is a targeted, monoclonal antibody that inhibits the cell-surface receptor c-KIT, also known as CD117. It is currently being evaluated as a primary therapeutic for mast cell diseases.
Lead Product(s): Briquilimab,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: JSP191
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
JSP191 (briquilimab) is a targeted, monoclonal antibody that inhibits CD117. It is currently being evaluated for mast cell diseases such as chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma, and for lower-risk MDS patients.
Lead Product(s): Briquilimab
Therapeutic Area: Immunology Product Name: JSP191
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
